222 related articles for article (PubMed ID: 27443507)
1. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Barajas RF; Butowski NA; Phillips JJ; Aghi MK; Berger MS; Chang SM; Cha S
Acad Radiol; 2016 Sep; 23(9):1073-82. PubMed ID: 27443507
[TBL] [Abstract][Full Text] [Related]
2. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.
Thomas A; Rosenblum M; Karimi S; DeAngelis LM; Omuro A; Kaley TJ
CNS Oncol; 2018 Jan; 7(1):7-13. PubMed ID: 29388793
[TBL] [Abstract][Full Text] [Related]
3. Utility of intravoxel incoherent motion magnetic resonance imaging and arterial spin labeling for recurrent glioma after bevacizumab treatment.
Miyoshi F; Shinohara Y; Kambe A; Kuya K; Murakami A; Kurosaki M; Ogawa T
Acta Radiol; 2018 Nov; 59(11):1372-1379. PubMed ID: 29471670
[TBL] [Abstract][Full Text] [Related]
4. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
5. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
7. Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
Cho SJ; Kim HS; Suh CH; Park JE
Korean J Radiol; 2020 Jul; 21(7):908-918. PubMed ID: 32524791
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
9. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
10. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
11. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
12. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
[TBL] [Abstract][Full Text] [Related]
13. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
14. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
[TBL] [Abstract][Full Text] [Related]
15. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
16. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.
Park YW; Ahn SS; Moon JH; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Neuroradiology; 2021 Nov; 63(11):1811-1822. PubMed ID: 33755766
[TBL] [Abstract][Full Text] [Related]
18. Centrally Reduced Diffusion Sign for Differentiation between Treatment-Related Lesions and Glioma Progression: A Validation Study.
Alcaide-Leon P; Cluceru J; Lupo JM; Yu TJ; Luks TL; Tihan T; Bush NA; Villanueva-Meyer JE
AJNR Am J Neuroradiol; 2020 Nov; 41(11):2049-2054. PubMed ID: 33060101
[TBL] [Abstract][Full Text] [Related]
19. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
[TBL] [Abstract][Full Text] [Related]
20. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
